This discrepancy in the literature suggests that the relationship is complex and may be confounded by the significant and rapid weight loss induced by these agents, which is itself a known risk factor for gallstone formation
Clinical Studies 14.1 Glycemic Control in Adults with Type 2 Diabetes Mellitus Overview of Clinical Trials of FARXIGA in Adults with Type 2 Diabetes Mellitus FARXIGA has been studied in adult patients as monotherapy, in combination with metformin, pioglitazone, sulfonylurea (glimepiride), sitagliptin (with or without metformin), metformin plus a sulfonylurea, or insulin (with or without other oral antidiabetic therapy), compared to a sulfonylurea (glipizide), and in combination with a GLP-1 receptor agonist (exenatide extended release) added on to metformin
Br J Dermatol 164:1403-1405 Urbanski U et al
These side effects are often linked to nutrition
Additionally, Rybelsus slows gastric emptying, which moderates the rate at which nutrients enter the small intestine and are absorbed
Heres where I have to be most careful